DCTH (Delcath Systems) Piotroski F-Score: 7 (As of Jun. 24, 2026) — 75% Above Median


DCTH Delcath Systems Inc DCTH
70 GF Score
Price $12.23
GF Value $36.67
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Delcath Systems Piotroski F-Score?

Delcath Systems DCTH -0.41% 70 Piotroski F-Score is 7 as of Jun. 24, 2026, which is 75% above its 10-year median of 4.00. GuruFocus rates DCTH with a GF Score™ of 70/100 and a GF Value™ of $36.67 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Delcath Systems ranks better than 92.42% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Delcath Systems has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Delcath Systems's Piotroski F-Score or its related term are showing as below:

DCTH' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Delcath Systems was 8. The lowest was 1. And the median was 4.

Delcath Systems  (NAS:DCTH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Delcath Systems Piotroski F-Score Related Terms


Delcath Systems Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Delcath Systems's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Delcath Systems Piotroski F-Score Chart

Delcath Systems Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 2.00 4.00 5.00 7.00

Delcath Systems Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 8.00 8.00 7.00 7.00

DCTH vs OFIX, VMD, CLPT: Piotroski F-Score Comparison

For the Medical Devices subindustry, Delcath Systems's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Delcath Systems Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Delcath Systems's Piotroski F-Score falls into.


DCTH
70GF Score
Delcath Systems Inc DCTH
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 2.697 + 0.83 + -1.896 + -1.07 = $0.56 Mil.
Cash Flow from Operations was 7.293 + 4.772 + 8.248 + 0.857 = $21.17 Mil.
Revenue was 24.156 + 20.563 + 20.728 + 24.994 = $90.44 Mil.
Gross Profit was 20.838 + 17.939 + 17.718 + 21.258 = $77.75 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(87.319 + 116.876 + 124.295 + 123.632 + 124.838) / 5 = $115.392 Mil.
Total Assets at the begining of this year (Mar25) was $87.32 Mil.
Long-Term Debt & Capital Lease Obligation was $0.82 Mil.
Total Current Assets was $120.27 Mil.
Total Current Liabilities was $10.70 Mil.
Net Income was -13.741 + 1.864 + -3.398 + 1.069 = $-14.21 Mil.

Revenue was 7.766 + 11.2 + 15.1 + 19.784 = $53.85 Mil.
Gross Profit was 6.247 + 9.56 + 12.974 + 16.939 = $45.72 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(36.099 + 33.913 + 31.681 + 76.589 + 87.319) / 5 = $53.1202 Mil.
Total Assets at the begining of last year (Mar24) was $36.10 Mil.
Long-Term Debt & Capital Lease Obligation was $0.91 Mil.
Total Current Assets was $84.35 Mil.
Total Current Liabilities was $5.29 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Delcath Systems's current Net Income (TTM) was 0.56. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Delcath Systems's current Cash Flow from Operations (TTM) was 21.17. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=0.561/87.319
=0.00642472

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-14.206/36.099
=-0.39352891

Delcath Systems's return on assets of this year was 0.00642472. Delcath Systems's return on assets of last year was -0.39352891. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Delcath Systems's current Net Income (TTM) was 0.56. Delcath Systems's current Cash Flow from Operations (TTM) was 21.17. ==> 21.17 > 0.56 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0.815/115.392
=0.00706288

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0.906/53.1202
=0.01705566

Delcath Systems's gearing of this year was 0.00706288. Delcath Systems's gearing of last year was 0.01705566. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=120.269/10.698
=11.2421948

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=84.349/5.287
=15.95403821

Delcath Systems's current ratio of this year was 11.2421948. Delcath Systems's current ratio of last year was 15.95403821. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Delcath Systems's number of shares in issue this year was 36.021. Delcath Systems's number of shares in issue last year was 39.511. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=77.753/90.441
=0.85970964

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=45.72/53.85
=0.84902507

Delcath Systems's gross margin of this year was 0.85970964. Delcath Systems's gross margin of last year was 0.84902507. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=90.441/87.319
=1.03575396

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=53.85/36.099
=1.49173107

Delcath Systems's asset turnover of this year was 1.03575396. Delcath Systems's asset turnover of last year was 1.49173107. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+1+1+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Delcath Systems has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Delcath Systems (DCTH) has a Piotroski F-Score of 7 as of Jun. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Delcath Systems and its competitors. This is 75% above median its historical median of 4.00. Over the past decade, Delcath Systems' Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, Delcath Systems ranks #61 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 7.6%.
Is Delcath Systems' Piotroski F-Score too high?
Delcath Systems' current Piotroski F-Score of 7 is 75% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Delcath Systems' value of 7 is 40% above this industry median. Based on the distribution chart, Delcath Systems ranks #61 out of 805 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Delcath Systems has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Delcath Systems' Piotroski F-Score compare to OFIX and VMD?
According to the Medical Devices & Instruments industry distribution chart, Delcath Systems ranks #61 out of 805 companies for Piotroski F-Score. This places Delcath Systems in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Delcath Systems' value of 7 is 40% above this benchmark. Historically, Delcath Systems' own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Delcath Systems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Delcath Systems's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Delcath Systems and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Delcath Systems's current Piotroski F-Score is 7, which is 75% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delcath Systems stock overvalued right now?
Based on GuruFocus' analysis, Delcath Systems (DCTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $36.67, compared to a current price of $12.23 — trading 66.6% below its estimated fair value. The current Piotroski F-Score is 7, which is 75% above median its 10-year median of 4.00 and 40% above the Medical Devices & Instruments industry median of 5.00. Delcath Systems' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Delcath Systems (DCTH), the current Piotroski F-Score is 7 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Delcath Systems (DCTH) Overvalued in 2026?

Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued. The current stock price of $12.23 is trading 66.6% below its estimated GF Value™ of $36.67. GuruFocus considers Delcath Systems to be Significantly Undervalued.

Key valuation signals for DCTH:

  • Piotroski F-Score: 7 (75% above median its 10-year median of 4.00)
  • GF Value™: $36.67 vs. price of $12.23 (66.6% below fair value)
  • GF Score™: 70/100 with 3 warning signs
  • Industry Position: 40% above the Medical Devices & Instruments median (#61 of 805)

No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Delcath Systems Business Description

Other Exchanges DV3R:Germany
Address 566 Queensbury Avenue, Queensbury, NY, USA, 12804
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
70GF Score

Get the complete analysis for DCTH

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.23
Price
$36.67
GF Value